| Literature DB >> 31668191 |
Simon Tiberi1, Alimuddin Zumla2, Giovanni Battista Migliori3.
Abstract
Multidrug-resistant tuberculosis (MDR-TB) is a growing global public health threat. MDR-TB affects more than a half-million people worldwide and is characterized by significant morbidity and mortality. New rapid diagnostic methods like GeneXpert and availability of new MDR-TB drugs and shorter treatment regimens hold promise of more patients diagnosed and put on treatment. Major challenges of lack of adequate resources, poverty, and limited access to health care continue to hamper efforts. This article reviews epidemiology, clinical features, management, and treatment, with new updates and recent changes in guidelines that offer patients better tolerated and shorter regimens for enabling therapeutic outcomes.Entities:
Keywords: Drug-resistant tuberculosis; GeneXpert MTB/RIF Assay; Multidrug-resistant TB (MDR-TB); Rehabilitation; Surgery; Treatment guidelines; Workplace safety
Mesh:
Substances:
Year: 2019 PMID: 31668191 DOI: 10.1016/j.idc.2019.09.002
Source DB: PubMed Journal: Infect Dis Clin North Am ISSN: 0891-5520 Impact factor: 5.982